Skip to main content
SpringerLink
Log in

Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Fibromyalgia (FM) primarily affects women, and it is increasingly recognized by health care providers as more patients seek assistance for their chronic pain conditions. FM patients suffer from reduced quality of life, daily functioning and productivity. A single FM patient can cost society tens of thousands of dollars each year, with the overall expense increasing alongside disease severity. Indirect costs account for the majority of total expenditures and involve losses in productivity, reduced work hours, absenteeism, disability, unemployment, early retirement, informal care and other out-of-pocket costs. Health care utilization increases in concert with the severity of illness. Moreover, FM patients often have several comorbid illnesses (e.g. depression, anxiety and sleep disturbances), resulting in extreme escalation of overall health care expenditures. Medications with the best efficacy in the treatment of FM include the tricyclic antidepressants amitriptyline and nortriptyline, cyclobenzaprine (a skeletal muscle relaxant), tramadol, duloxetine, milnacipran, pregabalin and gabapentin. Corticosteroids, nonsteroidal anti-inflammatory drugs, benzodiazepines and opioid analgesics, with the exception of tramadol, are not considered efficacious. Medication selection should be individualized and influenced by the severity of illness and the presence of comorbidities and functional disabilities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  2. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther. 2010;17(4):418–39.

    PubMed  Google Scholar 

  3. Roskell NS, Beard SM, Zhao Y, et al. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11(6):516–27.

    Article  PubMed  Google Scholar 

  4. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey of five European countries. Semn Arthritis Rheum. 2010;39(6):338–53.

    Google Scholar 

  5. Mannerkorpi K, Gard G. Hinders for continue work among persons with fibromyalgia. Musculoskelet Disord. 2012;13:96. doi:10.1186/1471-2474-13-96.

    Article  Google Scholar 

  6. Grodman I, Buskila D, Arson Y, et al. Understanding fibromyalgia and its resultant disability. Isr Med Assoc J. 2011;13(12):769–72.

    PubMed  Google Scholar 

  7. Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27(7):547–59.

    Article  PubMed  Google Scholar 

  8. Arnold LM, Hudson JI, Keck PE Jr, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67(8):1219–25.

    Article  PubMed  Google Scholar 

  9. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14(2):127, e1–8.

    Google Scholar 

  10. Moore RA, Straube S, Paine J, Phillips CJ, Deny S, McQuay HJ. Fibromyalgia moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain. 2010;149(2):360–4.

    Article  PubMed  Google Scholar 

  11. Knight T, Schaefer C, Chandran A, et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clin Econ Outcomes Res. 2013;5:171–80. doi:10.2147/CEOR.S41111.

    Article  Google Scholar 

  12. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. J Clin Pract. 2007;61(9):1498–508.

    Article  CAS  Google Scholar 

  13. Silverman S, Dukes EM, Johnston SS, et al. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25(4):829–40.

    Article  PubMed  Google Scholar 

  14. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic costs and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30(6):1318–25.

    PubMed  Google Scholar 

  15. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia medical comorbidity, health care costs, and work loss. J Occup Environ Med. 2008;50(1):13–24.

    Article  PubMed  Google Scholar 

  16. Wolfe F, Clauw DJ, Fitzcharles M, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–10.

    Article  Google Scholar 

  17. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome. J Clin Rheumatol. 2013;19(2):72–7.

    Article  PubMed  Google Scholar 

  18. Arnold JM, Clauw DJ, Dunegan LJ, Turk DC. A framework for fibromyalgia management for primary care providers. May Clin Proc. 2012;87(5):488–96.

    Article  Google Scholar 

  19. Smith HS, Bracken D, Smith JM. Pharmacotherapy for fibromyalgia. Front Pharmacol. 2011;2:17 (Epub 2011 Mar 31).

    Article  PubMed Central  PubMed  Google Scholar 

  20. Firestone KA, Holton KF, Mist SD, Wright CL, Jones KD. Optimizing fibromyalgia management. Nurs Pract. 2012;37(4):12–21.

    Article  Google Scholar 

  21. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297–302.

    Article  PubMed  Google Scholar 

  22. Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs. 2010;70(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  23. Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ. 2012;15(3):481–92.

    Article  PubMed  Google Scholar 

  24. Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin. 2010;26(4):965–75.

    Article  CAS  PubMed  Google Scholar 

  25. Beard SM, Roskell N, Le TK, et al. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ. 2011;14(4):463–76.

    CAS  PubMed  Google Scholar 

  26. Ornelas HA, Buzzo AR, Garcia L, et al. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico. Reumatol Clin. 2012;8(3):120–7.

    Google Scholar 

  27. Cappelleri JC, Bushmakin AG, Zlateva G, Chandran A. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin. J Med Econ. 2013;16(1):55–61.

    Article  PubMed  Google Scholar 

  28. Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil. 2005;27(12):685–94.

    Article  CAS  PubMed  Google Scholar 

  29. Henriksson CM, Liedberg GM. Factors of importance for work disability in women with fibromyalgia. J Rhematol. 2000;27(5):1271–6.

    CAS  Google Scholar 

  30. Assefi NP, Coy TV, Uslan D, et al. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions. J Rheumatol. 2003;39(4):804–8.

    Google Scholar 

  31. Gerdle B, Bjork J, Coster L, et al. Prevalence of widespread pain and associations with work status: a population study. BMC Musculoskelet Disord. 2008;9:102.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kurtze N, Gundersen KT, Sveback S. The impact of perceived physical dysfunction, health habits and affective symptoms on employment status among fibromyalgia support group members. J Musculoskelet Pain. 2001;9(2):39–53.

    Article  Google Scholar 

  33. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13(4):199–201.

    Article  CAS  PubMed  Google Scholar 

  34. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8(1):27.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Evans CJ, Parthan A, Le K. Economic and humanistic burden of fibromyalgia in the USA. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):303–14.

    Article  PubMed  Google Scholar 

  36. Kivimaki M, Leino-Arjas P, Kaila-Kangas L, et al. Increased absence due to sickness among employees with fibromyalgia. Ann Rheum Dis. 2007;66(1):65–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate, and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Angst F, Verra ML, Lehmann S, et al. Responsiveness of five condition-specific and generic outcomes assessment instruments for chronic pain. BMC Med Res Methodol. 2008;8:26.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Birtane M, Uzuncan K, Tastekin N, et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol. 2007;26(5):679–84.

    Article  PubMed  Google Scholar 

  41. Perrot S, Winkelmann A, Dukes E, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract. 2010;64(8):1100–8.

    Article  CAS  PubMed  Google Scholar 

  42. Yilmaz F, Sahin F, Ergoz E, et al. Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol. 2008;27(3):327–32.

    Article  PubMed  Google Scholar 

  43. Pagano T, Matsutani LA, Ferreira EA, et al. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J. 2004;122(6):252–8.

    Article  PubMed  Google Scholar 

  44. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115–26.

    CAS  PubMed Central  PubMed  Google Scholar 

  45. Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31(7):1391–8.

    PubMed  Google Scholar 

  46. Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumotol. 2004;31(8):1621–9.

    Google Scholar 

  47. Hughes G, Martines C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum. 2006;54(1):177–83.

    Article  PubMed  Google Scholar 

  48. Annemans L, Wesseley S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895–902.

    Article  CAS  PubMed  Google Scholar 

  49. Chandran A, Schaefer C, Ryan K, et al. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age US adults. JMCP. 2012;18(6):415–26.

    PubMed  Google Scholar 

  50. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40(9):1560–70.

    Article  CAS  PubMed  Google Scholar 

  51. Haviland MG, Banta JE, Przekop P. Hospitalisation charges for fibromyalgia in the United States, 1999–2007. Clin Exp Rheumatol. 2012;30(supple 74):129–35.

    PubMed  Google Scholar 

  52. Kim SK, Kim SH, Lee CK, et al. Effect of fibromyalgia syndrome on the health-related quality of life and economic burden in Korea. Rheumatology. 2013;52(2):311–20.

    Article  CAS  PubMed  Google Scholar 

  53. Winkelmann A, Perrot S, Schaefer C, et al. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy. 2011;9(2):125–36.

    Article  PubMed  Google Scholar 

  54. Perrot S, Schaefer C, Knight T, et al. Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains. BMC Musculoskelet Disord. 2012;13:22. doi:10.1186/1471-2474-13-22.

  55. Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosin spondylitis. Ann Rheum Dis. 2005;64(3):396–402.

    CAS  PubMed Central  PubMed  Google Scholar 

  56. Rivera J, Rejas-Gutierrez J, Vallego MA, et al. Prospective study of the use of healthcare resources and economic costs in patients with fibromyalgia after treatment in routine medical practice. Clin Exp Rheumatol. 2012;30(Suppl 74):S31–8.

    Google Scholar 

  57. Zijlstra TR, Braakman-Jansen LM, Taal E, et al. Cost-effectiveness of spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford). 2007;46(9):1454–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The author reports received no funding to write this manuscript and has no relevant conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Pharmacotherapy, College of Pharmacy, Washington State University, Riverpoint Campus, PO Box 1495, Spokane, WA, 99210-1495, USA

    Tracy L. Skaer

Authors
  1. Tracy L. Skaer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy L. Skaer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skaer, T.L. Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden. PharmacoEconomics 32, 457–466 (2014). https://doi.org/10.1007/s40273-014-0137-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-014-0137-y

Keywords

Search

Navigation